ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cohort Study"

  • Abstract Number: 0623 • ACR Convergence 2020

    Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort

    Neha Chiruvolu1, Muntarin Karim2, Patil Injean3, Sandy Lee3, Karina Torralba4, Christina Downey3, Mehrnaz Hojjati5, Loomee Doo5, Donna Jose6, Deepa Panikkath3, Micah Yu5, Anna Lafian5, Marven Cabling5 and Vaneet Sandhu7, 1UC Riverside School of Medicine, Riverside, CA, 2Loma Linda University Health System, Loma Linda, CA, 3Loma Linda University Medical Center, Redlands, CA, 4Loma Linda University School of Medicine, Redlands, CA, 5Loma Linda University Medical Center, Loma Linda, CA, 6Loma Linda University Medical Center, Ontario, CA, 7Loma Linda University, Loma Linda, CA

    Background/Purpose: Cytokine Release Syndrome (CRS) or Macrophage Activation Syndrome (MAS) is a life threating hyperinflammatory condition that can complicate rheumatic disease as well as infections…
  • Abstract Number: 1082 • ACR Convergence 2020

    The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect

    Dmitriy Cherny1 and Carrie Richardson1, 1Rush University Medical Center, Chicago, IL

    Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…
  • Abstract Number: 1492 • ACR Convergence 2020

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes

    Yukiko Kimura1, George Tomlinson2, Laura Schanberg3, Mary Ellen Riordan4, Anne Dennos5, Vincent Del Gaizo6, Katherine Murphy7, Pamela F. Weiss8, Brian Feldman9 and Sarah Ringold10, 1Hackensack Meridian School of Medicine, Hackensack, NJ, 2Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, 3Duke University Medical Center, Durham, NC, 4Hackensack University Medical Center, Westwood, NJ, 5Duke University, Durham, NC, 6Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, 7Lousiana Department of Public Health, New Orleans, LA, 8Children's Hospital of Philadelphia, Philadelphia, 9The Hospital for Sick Children, Toronto, ON, Canada, 10Seattle Children's, Seattle, WA

    Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
  • Abstract Number: 1902 • ACR Convergence 2020

    Determinants of Physician Global Assessment and Influence of Contextual Factors in Early Axial Spondyloarthritis

    Fumio Hirano1, Robert Landewé2, Floris van Gaalen3, Désirée van der Heijde4, Cecile Gaujoux-Viala5 and Sofia Ramiro6, 1Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, 2Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 3Leiden University Medical Center (LUMC), Leiden, Netherlands, 4Leiden University Medical Center, Leiden, Netherlands, 5Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, 6Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: In rheumatic and musculoskeletal diseases, physician global assessment (PhGA) is a major factor of treatment decision. However, it is not well-known which disease manifestations…
  • Abstract Number: 0206 • ACR Convergence 2020

    Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)

    Naoto Tamura1, Eiichi Tanaka2, Eisuke Inoue3, Yuri Yoshizawa4, Shigeru Matsumoto5, Hisashi Yamanaka6 and Masayoshi Harigai7, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, 2Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 3Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, 4Bristol-Myers Squibb K.K., Tokyo, Japan, 5Ono Pharmaceutical Co., Ltd., Tokyo, Japan, 6Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, 7Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…
  • Abstract Number: 0630 • ACR Convergence 2020

    “No Benefit from a Strict Immobilization in Vertebral Osteomyelitis” Vertebral Immobilization and Neurological Complication in Acute Pyogenic Vertebral Osteomyelitis: SPONDIMMO, a Prospective Cohort of 250 Patients

    Adrien Le Pluart1, COIFFIER Guillaume2, Christelle Darrieutort1, CORMIER Grégoire3, GODOT Sophie4, Sebastien Ottaviani5, Gaetane Nocturne6, MEROT Oriane7, COUDERC Marion8, HOPPE Emmanuel9, MULLEMAN Denis10, Benoit Le Goff11 and Geraldine Bart12, 1Nantes University Hospital Center, Nantes, France, 2Rennes University Hospital Center, Rennes, France, 3La Roche Sur Yon Hospital Center, La Roche Sur Yon, France, 4Paris Croix Saint Simon Hospital Center, Paris, France, 5Rheumatology Department, Bichat hospital, APHP, Paris, France, 6Rheumatology Department, Bicetre Hospital, APHP, France, Le Kremlin-Bicêtre, France, 7Saint Nazaire Hospital Center, Saint-Nazaire, Pays de la Loire, France, 8Clermont Ferrant University Hospital Center, Clermont Ferrand, France, 9Angers University Hospital Center, Angers, France, 10Tours University Hospital Center, Tours, France, 11Nantes University Hospital, Nantes, Pays de la Loire, France, 12Rennes University Hospital Center, Rennes, Bretagne, France

    Background/Purpose: Vertebral osteomyelitis (VO) can be associated with neurological complications. We showed in a previous study that they occurred in 40% of patients with VO.…
  • Abstract Number: 1108 • ACR Convergence 2020

    Cartilage Biomarkers s-Coll2-1 and s-Coll2-1NO2 Are Associated with Knee Osteoarthritis MRI Features and Predict Disease Worsening

    Yves Henrotin1, Anne-Christine Hick2, Berenice Costes3, Alain Labasse3, Thierry Conrozier4, Michel Malaise5, Yves Maugars6, Franz Pelousse7, Jean-Marc Lemaire8, Cedric Tits9, Thibault Helleputte9 and Damien Loeuille10, 1University of Liège, Liège, Belgium, 2Artialis SA, Liège, Belgium, 3Artialis SA, Liege, Belgium, 45. Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France, 5University of Liège, Liege, Belgium, 6Service de rhumatologie, Hôtel-Dieu, CHU de Nantes, Nantes, France, 7SODIRAY, Solution Diagnostique Radiologique, Liège, Belgium, 8SODIRAY, Solution Diagnostique Radiologique, Liege, Belgium, 9Data-Driven Precision Medicine, DNAlytics, Louvain-la-Neuve, Belgium, 10CHU NANCY Rheumatology, NANCY

    Background/Purpose: To identify if biochemical markers s-Coll2-1, a peptide of type collagen and its nitrated from, s-Coll2-1NO2 are associated to knee osteoarthritis (OA), focusing on…
  • Abstract Number: 1498 • ACR Convergence 2020

    Pregnancy Outcomes in Patients with Axial Spondyloarthritis – a First Analysis of a European Collaboration of Pregnancy Registries

    Yvette Meissner1, Nathalie Costedoat-Chalumeau2, Frauke Foerger3, Doreen Goll4, Anna Molto5, Rebecca Özdemir6, Marianne Wallenius7, Anja Strangfeld8 and Rebecca Fischer-Betz9, 1Deutsches Rheuma-Forschungszentrum, Berlin, Germany, 2APHP, Université de Paris, Paris, France, 3University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland, 4Patient Research Partner, Berlin, Germany, 5Rheumatology Department, Cochin Hospital, Paris, Paris, France, 6Patient Research Partner, Duisburg, Germany, 7University Hospital and Norwegian University of Science and Technology, Trondheim, Norway, 8German Rheumatism Research Center, Berlin, Germany, 9Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) can affect women in their childbearing age. Data on pregnancy in axSpA patients are mainly retrospective and highly heterogeneous [1]. The…
  • Abstract Number: 2035 • ACR Convergence 2020

    Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design

    Robyn Domsic1, Shiyao Gao2, Maureen Laffoon2, Steven Wisniewski3, Robert Lafyatis4, Virginia Steen5 and Thomas Medsger6, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 4University of Pittsburgh, Arlington, MA, 5Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 6University of Pittsburgh School of Medicine, Verona, PA

    Background/Purpose: Clinical trials in early diffuse systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome have been largely negative.  This…
  • Abstract Number: 0225 • ACR Convergence 2020

    Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study

    Hawazin Alhazzani1, Reem Tashkandi1, Lamia Alzamel1, Haya Almalag1, Shiekha Alaujan1, Abdurhman Alarfaj1, Hussain Alarfaj1 and Mohammed Omair1, 1King Saud University, Riyadh, Saudi Arabia

    Background/Purpose: Biologics have been advocated by guidelines as effective therapies for rheumatoid arthritis (RA)1. Limited longitudinal studies investigated the prevalence and risk factors for developing…
  • Abstract Number: 0637 • ACR Convergence 2020

    Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time

    Benjamin Naovarat1, Francis Williams1 and John Reveille2, 1The University of Texas McGovern Medical School, Houston, TX, 2Department of Internal Medicine, University of Texas, Houston, TX

    Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
  • Abstract Number: 1109 • ACR Convergence 2020

    Pain in Women with Knee and/or Hip Osteoarthritis Is Related to Systemic Inflammation and to Adipose Tissue Dysfunction and Distribution: A Cross-sectional Metabolic Biomarkers Cohort Study

    Jeremie Sellam1, Anne-Christine Rat2, Soraya Fellahi3, Jean-Philippe Bastard4, Willy NGUEYON SIME5, Hang Korng EA6, Pascal Richette7, Jacqueline Capeau8, Francis Guillemin9 and Francis Berenbaum1, 1AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, 2Universite de Caen Normandie and Université de Lorraine, EA 4360, Caen, France, 3AP-HP INSERM, Paris, France, 4INSERM AP-HP UPEC, Paris, France, 5Universite de Lorraine, INSERM, CIC, Nancy, France, 6Universite de Paris, AP-HP, INSERM, paris, France, 7Department of Rheumatology, Lariboisière Hospital, Paris, France, 8INSERM Sorbonne Universite, Paris, France, 9Universite de Lorraine CIC INSERM, Nancy, France

    Background/Purpose: Beyond the link between metabolic diseases and osteoarthritis (OA) risk, some studies have suggested an association between metabolic syndrome or visceral obesity and OA-related…
  • Abstract Number: 1567 • ACR Convergence 2020

    Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)

    Despina Michailidou1, Ali R Khaki2, Guangyu Wang3, Leonidas Diamantopoulos2 and Petros Grivas2, 1Division of Rheumatology, University of Washington, Seattle, Washington, Seattle, WA, 2Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA, 3Department of Biostatistics, University of Washington, Seattle, Washington, Seattle, WA

    Background/Purpose: Patients with cancer treated with CPI can develop irAEs. Since immune changes may impact blood counts and ratios, we hypothesized that those would be…
  • Abstract Number: 0245 • ACR Convergence 2020

    Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record

    April Barnado1, Robert Carroll1 and Lee Wheless1, 1Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with patients often presenting with non-specific symptoms that can cause delays in diagnosis. Phenotype risk scores…
  • Abstract Number: 0672 • ACR Convergence 2020

    Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares

    Natalie McCormick1, Chio Yokose1, Clara Chen2, Tuhina Neogi3, David Hunter4, Hyon Choi5 and Yuqing Zhang6, 1Massachusetts General Hospital, Boston, MA, 2Boston University School of Public Health, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 6Massachusetts General Hospital, Harvard Medical School, Boston

    Background/Purpose: Cross-sectional radiologic evidence suggests monosodium urate crystal deposition among gout patients is a symmetrical phenomenon,1 but no study has examined the longitudinal patterns in…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology